RA0141

antibody from Oursmab

Targeting: CFD ADN, DF, PFD

ELISA (Recommended by provider)

Immunocytochemistry (Recommended by provider)

Flow cytometry (Recommended by provider)

Functional assay (Recommended by provider)

Antibody Data

Product number

RA0141

Provider

Oursmab

Product name

Lampalizumab (Biosimilar Reference Antibody) (CFD)

Antibody type

Monoclonal

Description

Lampalizumab (also known as RG-7417) was an investigational, humanized monoclonal antibody fragment (Fab) designed to target complement factor D (CFD). It was developed as a potential therapy for geographic atrophy (GA), the advanced, atrophic form of age-related macular degeneration (AMD). By specifically inhibiting factor D, a rate-limiting enzyme in the alternative complement pathway, Lampalizumab aimed to reduce chronic inflammation and complement-mediated damage to retinal cells. Despite promising early and mid-stage clinical results, it did not meet its primary efficacy endpoints in Phase III trials (CHROMA and SPECTRI) and its development for GA was discontinued.

Reactivity

Human

Vial size

100 ¦Ìg,1 mg,5 mg,10 mg,25 mg,50 mg,100 mg

Concentration

Bottled at the concentration indicated on the vial.

Storage

Store at -20¡ãC or -80¡ãC. Avoid repeated freeze.